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Abstract
Background: Neurons are highly polarized cells in which asymmetric axonal-dendritic distribution of proteins is
crucial for neuronal function. Loss of polarized distribution of the axonal protein tau is an early sign of Alzheimer’s
disease (AD) and other neurodegenerative disorders. The cytoskeletal network in the axon initial segment (AIS)
forms a barrier between the axon and the somatodentritic compartment, contributing to axonal retention of tau.
Although perturbation of the AIS cytoskeleton has been implicated in neurological disorders, the molecular triggers
and functional consequence of AIS perturbation are incompletely understood.
Results: Here we report that tau acetylation and consequent destabilization of the AIS cytoskeleton promote the
somatodendritic mislocalization of tau. AIS cytoskeletal proteins, including ankyrin G and βIV-spectrin, were downregulated
in AD brains and negatively correlated with an increase in tau acetylated at K274 and K281. AIS proteins were also
diminished in transgenic mice expressing tauK274/281Q, a tau mutant that mimics K274 and K281 acetylation. In primary
neuronal cultures, the tauK274/281Q mutant caused hyperdynamic microtubules (MTs) in the AIS, shown by live-imaging
of MT mobility and fluorescence recovery after photobleaching. Using photoconvertible tau constructs, we found that
axonal tauK274/281Q was missorted into the somatodendritic compartment. Stabilizing MTs with epothilone D to restore
the cytoskeletal barrier in the AIS prevented tau mislocalization in primary neuronal cultures.
Conclusions: Together, these findings demonstrate that tau acetylation contributes to the pathogenesis of
neurodegenerative disease by compromising the cytoskeletal sorting machinery in the AIS.
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Background
Maintenance of neuronal polarity is critical for directional
information flows in neuronal networks. Loss of the polar-
ized distribution of tau is a key early deficit in neurode-
generative diseases such as Alzheimer’s disease (AD) and
frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17) [1–6]. In healthy neurons, tau
is found predominantly in axons and at much lower levels
in dendrites [7, 8]. Under pathological conditions, how-
ever, the polarized distribution of tau is disrupted, as in
mouse models expressing tau with FTDP-17 mutations
[9–13]. In response to cellular insults such as amyloid beta
(Aβ), tau can be mislocalized to the somatodendritic
compartment, leading to destruction of the cytoskeletal
network in the dendrites [14, 15]. In AD mouse models,
dendritic tau mediates Aβ-induced excitotoxicity by
enabling transport of the kinase Fyn to dendritic spines
[16, 17]. Understanding the mechanisms of the polar-
ized distribution of tau is important. However, it is not
known how the cytoskeletal sorting machinery goes
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awry or what triggers the mislocalization of tau to the
somatodendritic compartment in a diseased neuron.
The axon initial segment (AIS), a subcellular region be-
tween the axon and the somatodendritic compartment,
generates action potentials and helps maintain neuronal po-
larity [18]. Consisting of microtubule (MT) bundles coated
with a dense submembrane protein network containing an-
kyrin G (AnkG), βIV-spectrin, and actin filaments [19, 20],
the AIS cytoskeleton forms a barrier between the axon and
the somatodendritic membrane [21] and regulates axonal
entry of cargoes that require selective transport [22]. Al-
though this barrier prevents axonal tau from invading the
somatodendritic compartment, pathologically modified tau
can bypass the AIS and be mislocalized from the axon [23].
The AIS cytoskeleton is perturbed in AD and other neuro-
degenerative diseases [24–26].
Increased acetyltransferase activity has been implicated
in neurodegenerative diseases [27], and acetylation of tau
increases in the early and moderate Braak stages of AD
[28]. In neurodegenerative diseases with tau inclusions,
acetylated tau accumulates with other pathological pro-
teins in the soma and neurites [29, 30]. Recently, we have
found that the acetylation of lysines 274 and 281 in the
MT-binding domain of tau is linked to cognitive decline in
human AD patients [31]. The most extensively described
activity of tau is its binding to MTs [32–34], and tau regu-
lates both static and dynamic features of neuronal MTs
[35–37]. Lysine acetylation in the MT-binding domain of
tau can impair its ability to stabilize MTs [38]; yet the
functional significance of tau acetylation in regulating the
neuronal cytoskeleton is not well understood.
In this study, we sought to determine whether AD-
relevant tau acetylation affects the stability of the AIS
cytoskeleton in vivo using transgenic mice expressing tau
with mutations to mimic acetylation. To investigate how
the tau-mediated disruption of AIS cytoskeleton leads to
loss of axonal distribution of tau, we monitored the move-
ment of photoconvertible tau in neuronal cultures. Finally,
we assessed pharmacological stabilization of MTs as a




cDNA encoding 2N4R human tau was cloned into pEGFP-
C1 vector (Clontech). In mApple-tagged tau plasmids,
EGFP in the pEGFP-C1 vector was replaced with mApple.
Tau mutations (K163/174/180/190Q, K274Q, K281Q,
K274/281Q, and K274/281R) were generated with the
QuickChange mutagenesis kit (Stratagene). The following
plasmids were gifts: GFP-tubulin (Dr. Ron Vale, University
of California, San Francisco), GFP-end-binding protein
(EB) 1 (Dr. Torsten Wittmann, University of California,
San Francisco), and GFP-EB3 (Dr. Niels Galjart, Erasmus
MC, Rotterdam).
Mice
The murine prion promoter (Mo.PrP) expression plasmid
(Mo.PrP.Xho) has been previously described [31, 39]. Hu-
man tauWT cDNA (2N4R) or cDNA with A820C (K274Q)
and A841C (K281Q) mutations were cloned into the Xho1
site of the Mo.PrP.Xho plasmid. The resulting Mo.PrP-
tauWT (tauWT) and Mo.PrP-tauK274/281Q (tauKQ) trans-
genes were microinjected into fertilized mouse oocytes from
the FVB/N genetic background and implanted into pseudo-
pregnant female mice. The founder lines with expression of
equivalent levels of tauWT and tauKQ, and higher levels of
tauKQ (tauKQhigh) in the FVB/N genetic background were
then crossed with C57BL/6 mice purchased from Jackson
Laboratory. All mice used for experiments were of mixed
FVB/N and C57BL/6 genetic background. Tail DNA from
offspring was genotyped by using the following primers: 5’
primer GGAGTTCGAAGTGATGGAAG, 3’ primer GGT
TTTTGCTGGAATCCTGG. Both male and female mice
were used for experiments. Mice were housed in a
pathogen-free barrier facility with a 12 h light-dark cycle
and ad libitum access to food and water. All animal proce-
dures were carried out under University of California, San
Francisco, Institutional Animal Care and Use Committee-
approved guidelines.
Human brain samples
Superior temporal gyrus of control and AD brains were
obtained from the Mount Sinai NIH Brain and Tissue
Repository (NBTR), provided by Dr. Vahram Haroutunian
(The Mount Sinai School of Medicine, New York). The
brain tissues were from early Braak stages 0–2 and late
Braak stages 5–6, and were extracted from patients in ages
of 70–103 years.
Cell culture and transfection
HeLa cells in Dulbecco’s modified Eagle’s medium supple-
mented with 10 % fetal bovine serum, 100 U/ml penicillin,
and 100 μg/ml streptomycin were grown at 37 °C in 5 %
CO2. Primary cultures were established from hippocampi
of Sprague-Dawley rat pups (Charles River Laboratories) on
postnatal day 0 or 1. Purified cells (50,000 per 300 μl of
neurobasal medium supplemented with B27; Life Tech-
nologies) were plated on poly-L-lysine-coated, glass-bottom
35-mm dishes (MatTek). After cells had attached, the
medium was replaced. At 6 or 7 DIV, the cells were trans-
fected with Lipofectamine 2000 (Life Technologies) and
DNA plasmids mixed 2:1 in OPTI-MEM (Life Technolo-
gies). After 30 min, the transfection medium (neurobasal
medium with kyneurenic acid) was replaced with condi-
tioned neurobasal medium supplemented with B27.
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Immunostaining and confocal imaging
Mice were transcardially perfused with 0.9 % saline, and
the brains were fixed in 4 % paraformaldehyde in PBS
for 48 h and then incubated in 30 % sucrose in PBS. For
antigen retrieval, coronal brain sections 30 μm thick
were cut with microtome and incubated in 10 mM citric
acid at 90 °C for 20 min. Floating brain sections were
permeabilized and blocked with PBS containing 0.3 %
Triton X-100 and 10 % normal goat serum (PBST) at
room temperature for 1 h. Sections were incubated first
with antibodies against AnkG (N106/36, NeuroMab)
and βIV-spectrin (gift from Dr. Matthew N. Rasband,
Baylor College of Medicine) at 4 °C overnight and then
with Alex Fluor 488- and 555-conjugated anti-mouse
and anti-rabbit antibodies (Life Technologies) at room
temperature for 1 h. Immunostaining with human brains
was performed as described previously [30]. Briefly,
cases were selected from the Neurodegenerative Disease
Brain Bank (NDBB) at the University of California, San
Francisco. 8 μm-thick sections were cut from paraffin
blocks and mounted on glass slides. Immunoperoxidase
staining was performed using an avidin-biotin complex de-
tection system (Vectastain ABC kit; Vector Laboratories).
Slides were pretreated for antigen retrieval by immersion
in 10 mM citric acid at 121 °C for 5 min. The primary anti-
body MAb359 [30] was incubated overnight at 4 °C and
biotinylated secondary antibody (Vector Laboratories) was
incubated at room temperature for 1 h. Slides were incu-
bated in Avidin/Biotinylated enzyme Complex (ABC) at
room temperature for 1 h followed by exposure to 3,3’-di-
aminobenzidine (DAB) substrate (Vector Laboratories).
For immunofluorescence, after antigen retrieval and block-
ing with 0.1 % Sudan Black solution, the primary anti-
bodies MAb359 [30], CP-13 (gift from Dr. Peter Davies,
Feinstein Institute for Medical Research), and AnkG
(N106/36, NeuroMab) were incubated overnight at 4 °C.
The DyLight 488-conjugated anti-mouse secondary anti-
body was incubated at room temperature for 1 h. AIS
Images were acquired with a Nikon Ti-E spinning-disk
confocal microscope and a 60X oil objective. Seven serial
optical sections (0.5 μm steps) were projected into a single
image to visualize the AIS. ImageJ software (NIH) was used
to analyze the intensity and length of the AIS.
MT-binding assay
MT binding assays in HeLa cells were performed as de-
scribed [40] with modifications. DNA plasmids of mApple-
mutant tau and GFP-WT tau were co-transfected into
HeLa cells. To assess the intracellular distribution of WT
and mutant tau, HeLa cells at 37 °C in 5 % CO2 were exam-
ined with a Nikon Ti-E spinning-disk confocal microscope
and a 60X oil objective 24–48 h after transfection. After
conversion of fluorescent RGB images into binary images,
ImageJ (NIH) was used to subtract a binary image of WT
tau from that of mutant tau. Cytoplasmic tau signals after
the image subtraction were calculated as the MT-unbound
tau index.
Measuring MT dynamics
Primary rat hippocampal neurons at DIV 6–7 were co-
transfected with GFP-EB3 and mApple-tau; the cells were
imaged at 37 °C in 5 % CO2 24 h after transfection. Live
time-lapse imaging was performed every second for 60 sec
with a Nikon Ti-E spinning disk confocal microscope and
a 60X oil objective. Movement of GFP-EB1 and GFP-EB3
comets were analyzed with the Matlab software package
plusTipTracker [41].
Fluorescence recovery after photobleaching (FRAP)
Primary rat hippocampal neurons at DIV 6–7 were co-
transfected with GFP-tubulin and mApple-tau, and imaged
24 h after transfection. Before imaging, the AIS was immu-
nolabeled with an antibody against the extracellular domain
of neurofascin (A12/18, NeuroMab) at 37 °C for 5 min.
After brief rinses with Neurobasal A media, Alexa Fluor
647 anti-mouse secondary antibody was applied at 37 °C
for 5 min. For FRAP experiments, we used a Nikon Ti
wide-field microscope and a 100X oil objective to examine
cells at 37 °C in 5 % CO2. An ROI (~5 μm) for photo-
bleaching was drawn in the center of the AIS, as judged
from anti-neurofascin staining. GFP-tubulin was bleached
with a 473-nm laser and fluorescence recovery was moni-
tored with a 488-nm laser. Time-lapse images were taken
every second for 60 sec. Images in which photobleaching
reduced fluorescence intensity by more than 70 % were an-
alyzed. The fluorescence signal was background subtracted
and quantified with ImageJ (NIH).
Photoconversion
Time-lapse live imaging during photoconversion was per-
formed as described using photoconvertible mEOS2-tau.
Primary rat hippocampal neurons at DIV 6–7 were trans-
fected with mEOS2-tau and imaged 48–72 h later with a
Nikon Ti-E spinning disk confocal microscope at 37 °C
with 5 % CO2. A ~30-μm portion of an axon segment
~30 μm from the cell body was subjected to photoconver-
sion with a 405-nm laser (two to three 300-ms exposures),
and red fluorescence images were acquired every 30 sec
for 30 min. Using ImageJ (NIH), changes in red fluores-
cence intensity was analyzed in both the cell body and a
distal axon ~30 μm away from the photoconversion site.
Changes in red fluorescence intensity were normalized to
the initial red fluorescence intensity from the photocon-
version site right after photoconversion.
Western blot
Human and mouse brain tissues were lysed in RIPA buffer
(50 mM Tris, pH. 7.4, 150 mM NaCl, 1 mM EDTA, 0.5 %
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Nonidet P-40) with histone deacetylase inhibitors (1 μM
trichostatin, 5 mM nicotinamide; both from Sigma), 1 mM
phenylmethyl sulfonyl fluoride (Sigma), phosphatase in-
hibitor cocktail (Roche), and protease inhibitor cocktail
(Sigma). Lysates were sonicated and centrifuged at 170,000
g at 4 °C for 15 min and at 18,000 g at 4 °C for 10 min.
Supernatants were collected, and protein concentrations
were measured by bicinchoninic acid assay (Pierce). Pro-
teins were resolved on 4–12 % SDS-PAGE and transferred
to nitrocellulose membranes. After blocking with nonfat
dry milk, the membranes were probed at 4 °C overnight
with primary antibodies: rabbit monoclonal MAb359 for
ac-K274 tau [30], rabbit monoclonal MAb63 for ac-K281
tau [31], mouse monoclonal anti-AnkG (N106/20, Neuro-
Mab), rabbit polyclonal anti-βIV-spectrin (gift from Dr.
Matthew N. Rasband, Baylor College of Medicine), mouse
monoclonal Tau5 (AHB0042, Life Technologies), mouse
monoclonal HT7 (MN1000, Thermo Scientific), mouse
monoclonal AT8 (MN1020, Thermo Scientific), mouse
monoclonal 12E8 (Prothena Biosciences), mouse monoclo-
nal PHF-1 (gift from P. Davies), and mouse monoclonal
anti-GAPDH (MAB374, Millipore). The membranes were
then incubated with HRP-conjugated secondary antibodies
at room temperature for 1 h. Immunoblots were visualized
by enhanced chemiluminescence (Thermo Scientific) and
quantified by ImageJ software (NIH).
Statistical analyses
Data were analyzed with GraphPad Prism 5 and STATA12.
Differences between groups were assessed with the un-
paired t test, one-way ANOVA with post-hoc test, and
mixed-model linear regression analysis as indicated. Longi-
tudinal data were fitted with mixed-model linear regression
using the xtmixed command from STATA 12. The linear
relationship between two variables was analyzed by Pear-
son’s correlation analysis after natural log transformation.
Results
AIS cytoskeletal proteins are downregulated in human AD
brains
AIS filtering defects have been observed in primary neurons
with familial AD mutations [24] and with Aβ exposure [25].
To examine the AIS in AD brain, we performed immuno-
staining of AnkG in the frontal cortex of AD patients. Inter-
estingly, we observed reduced levels of AnkG in the AIS in
AD brain compared to control brain (Fig. 1a). Immunoblot
analyses revealed a significant decrease in levels of AIS cyto-
skeletal proteins, including AnkG and βIV-spectrin, in AD
patients at late Braak stages compared to early Braak stages
(Fig. 1b, c; Table 1). In AD brains at late Braak stages,
acetyl-K274 and -K281 on tau were detected by the acetyl-
lysine-specific MAb359 and MAb63 tau antibodies [31],
respectively. Levels of acetyl-K274 were significantly higher
at late Braak stages than early stages (Fig. 1b, c). Acetyl-
K274 tau detected with MAb359 was highly enriched in
intraneuronal tau inclusions in human tauopathy brains
(Additional file 1: Figure S1A-C) [30]. Acetyl-K274 tau was
localized in the cytoplasm of neurons of FTDP-17 patients
(Additional file 1: Figure S1A) and also in the corticobasal
bodies of patients with A152T mutation (Additional file 1:
Figure S1B), which is linked with increased risk of AD and
progressive supranuclear palsy (PSP) [42]. In AD patients,
acetyl-K274 tau was localized in neurofibrillary tangles
(Additional file 1: Figure S1C). Notably, the decrease in
AnkG and βIV-spectrin levels in AD brains correlated with
increased acetyl-K274 and -K281 on tau (Fig. 1d), raising
the possibility that acetylated tau downregulates AIS cyto-
skeletal proteins in AD.
Neuronal expression of K274/281Q tau reduces levels of
AIS cytoskeleton in vivo
Next, we examined whether acetylated tau destabilizes the
AIS cytoskeleton using transgenic mice with mouse prion
promoter-driven expression of wild-type 2N4R human tau
(tauWT) or tau with K274 and K281 mutated to glutamines
to mimic acetylation (tauKQ) [31]. In the cortex, tauKQ
and tauWT mice had comparable human tau levels,
whereas tauKQhigh mice had significantly greater levels of
tauKQ transgene expression (Fig. 2a, b). To investigate the
effect of tauKQ on the AIS cytoskeleton, we analyzed βIV-
spectrin and AnkG immunostaining in the somatosensory
cortex of 2-month-old tauKQhigh mice. There was a signifi-
cant decrease in βIV-spectrin and AnkG present at the AIS
in tauKQhigh mice compared to non-transgenic controls
(Fig. 2c-e), suggesting that acetylation at K274/281 can lead
to destabilization of the AIS cytoskeleton in vivo. The
length of the AIS cytoskeleton, which can be modulated by
external stimuli [43, 44], did not differ in tauKQhigh and
non-transgenic control mice (Fig. 2f). To exclude a possi-
bility that AIS destabilization in tauKQhigh mice is driven
by overexpression of tau transgene per se and is independ-
ent of acetyl-tau mimicking mutations, we further analyzed
the AIS proteins in 10–12-month-old transgenic mice
expressing equivalent levels of tauWT and tauKQ [31]
(Fig. 2e). There was a significant reduction of both βIV-
spectrin and AnkG intensity in the cortex of tauKQ mice
compared to tauWT mice in 10–12 months (Fig. 2g-i). In
the aged tauKQ mice, the AIS length measured by AnkG
labeling was shorter than in tauWT mice (Fig. 2j), suggest-
ing that prolonged expression of acetyl-tau mimic also
compromises the integrity of the AIS besides reducing the
levels of AIS proteins.
K274/281Q tau expression increases MT dynamics in primary
neurons
Acetylation at K274 and K281 in the MT-binding domain
of tau occurs in human AD brains (Fig. 1b, c). Posttransla-
tional modifications of tau in the MT-binding domain can
Sohn et al. Molecular Neurodegeneration  (2016) 11:47 Page 4 of 13
affect its binding affinity for MTs [45–47]. To examine the
effect of acetylation at K274/K281 on tau binding to MTs,
we mutated K-to-Q to mimic acetyl-lysine or K-to-R to
block acetylation. Substitution of lysine (K) to either glu-
tamine (Q) or arginine (R) has been widely used in a num-
ber of studies to determine effects of acetylation of
specific lysine residues on protein functions of histones,
transcription factors, and enzymes [48–52]. Importantly,
this lysine substitution faithfully represents the functional
impact of acetylation/deacetylation on tau [31, 53, 54]. To
assess the binding affinity, we analyzed cells expressing
mApple-tauWT and GFP-tau mutants in a competitive
MT-binding assay [40]. In HeLa cells co-transfected with
mApple-tauWT and GFP-tubulin, tauWT co-localized
with MTs visualized by GFP-tubulin, indicating attach-
ment of WT tau to MTs (Additional file 1: Figure S2A). If
a tau mutant has a lower affinity for MTs, it exhibits a



















































































































































































































Fig. 1 Levels of AIS cytoskeletal proteins are downregulated in human AD brains and correlate negatively with ac-K274 and ac-K281 tau levels.
a Representative images of AnkG immunostaining in human control and AD brains. Scale bars, 10 μm. b, c Representative western blots and
quantification of levels of AnkG, βIV-spectrin, ac-K274 tau, and ac-K281 tau in human AD brains. n = 11–15 samples/group. *p < 0.05, **p < 0.01,
unpaired t test. d Correlation analyses between AnkG or βIV-spectrin and ac-K274 or ac-K281 tau. Pearson correlation analyses after natural log
transformation. Values are mean ± SEM (c)
Sohn et al. Molecular Neurodegeneration  (2016) 11:47 Page 5 of 13
unbound tau index which is calculated by subtracting the
fluorescence signal of tauWT from the tau mutant. The
unbound tau index for tauK274/281Q was significantly
higher than tauWT, whereas tauK274/281R showed similar
binding affinity as tauWT (Additional file 1: Figure S2B, C),
suggesting that acetylation at K274/281 reduces tau binding
to MTs. Binding of individual mutant tauK274Q did not
change, and that of tauK281Q was modestly reduced. K-to-
Q mutations outside the MT-binding domain (K163/174/
180/190Q; 4KQ(N)) did not affect the unbound tau index,
as expected (Additional file 1: Figure S2C). The difference
in the amount of unbound cytoplasmic tau is unlikely due
to tau expression levels, as tauK274/281Q and tauWT were
expressed at similar levels (Additional file 1: Figure S2D),
and the unbound tau index did not correlate with tau levels
(p = 0.19, Pearson correlation analysis).
Tau isoforms with different MT-binding affinities differ
in their effects on the dynamic behavior of MTs [55, 56].
To determine whether acetylation at K274/281 affects
MT dynamics in living cells, we tracked the movement
of individual MTs by using GFP-tagged ending-binding
(EB) proteins that bind to MT plus-ends [57]. The rates
of movement were calculated in an unbiased fashion
with plusTipTracker, which faithfully tracks EB comets
from time-lapse images of living cells [41].
We co-transfected primary rat hippocampal neurons at
6–7 DIV with GFP-EB3 and mApple-tau constructs. EB
comets were imaged 24 to 48 h after transfection, and MT
dynamics were analyzed (Fig. 3a, b). The rate of move-
ment was significantly higher in neurons expressing
tauKQ than in those expressing tauWT (Fig. 3c). The
levels of tauWT and tauKQ did not differ (Fig. 3d), and
the rates of movement of EB comets did not correlate with
tau levels (p = 0.37, Pearson correlation analysis).
K274/281Q tau expression leads to hyperdynamic MTs in
the AIS
The stability of neuronal MTs varies depending on the
cellular compartment. MTs in the AIS are highly stabilized
by modifications and bundling and function as a barrier to
maintain the polarized distribution of tau in axons [20, 23,
58]. Since the acetyl-tau mimic increased MT dynamics in
neurons, we next examined the effect of tau acetylated at
K274/281 on the stability of the MTs in the AIS by FRAP.
We also suspected that the compromised integrity of βIV-
spectrin and AnkG induced by the acetyl-tau mimic
(Fig. 2c-J) could contribute to altering the stability of MTs
in the AIS because submembranous cytoskeletal proteins
are connected to MTs in the AIS [20, 59].
Rat hippocampal neurons at 6–7 DIV were co-transfected
with GFP-tubulin and mApple-tau constructs; 24 h later, we
labeled the AIS of live neurons with an antibody against the
extracellular domain of neurofascin, located in the plasma
membrane of the AIS [59]. The neurofascin antibody delin-
eated the AIS during live imaging (Fig. 4a), enabling us to
photobleach GFP-tubulin in a segment of the AIS. Monitor-
ing of the GFP-tubulin signal for 1 min after photobleaching
showed a significantly faster fluorescence recovery rate in
cells expressing tauKQ than in those expressing similar
levels of tauWT (Fig. 4b, c), consistent with destabilization
of MTs in the AIS by acetylated tau.
K274/281Q tau expression leads to the somatodendritic
mislocalization of tau, which can be attenuated by EpoD
Since the AIS is implicated in restricting tau distribution
in the axon [23], we suspected that weakening of the
AIS barrier by acetylated tau could lead to the mislocali-
zation of axonal tau. Photoconvertible tau constructs
were used to monitor the movement of tau in rat hippo-
campal neurons. At DIV 6–8, the cells were transfected
with mEOS2-tau construct that turns red upon UV illu-
mination. Tau was targeted for photoconversion in an
AIS segment ~30 μm away from the cell body, and
Table 1 AD human brain samples from superior temporal gyrus




2010 0 0 18
1248 0 0 16.8
1036 0 0 4.2
1004 1 0 5
1180 1 0 28.3
1028 1 0 40.9
1279 2 0 21.7
546 2 0 4.8
1040 2 0 4.8
776 2 0 4.1
1088 2 0 14.9
625 5 0.4 7.1
399 5 9.7 3
247 5 8.4 7.3
326 5 25.2 2.9
675 5 18.4 2.2
9 5 15.6 1.8
607 6 7.6 3.9
611 6 3.04 1.5
1203 6 6.4 3
736 6 9.2 4.3
649 6 10.8 7.3
992 6 6 3.3
505 6 12 3.3
350 6 13.2 3.5
697 6 9.2 12.3
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influx of tau into the somatodendritic compartment was
monitored (Fig. 5a; Additional file 2: Movie 1, Additional
file 3: Movie 2). As judged from the increase in fluores-
cence intensity, the influx was much greater with tauKQ
than tauWT or tauK274/281R (tauKR) (Fig. 5b, c). The
higher influx rate suggests that acetylation at K274/281
enabled tau to bypass the sorting barrier in the AIS. In the
distal axons, cells expressing tauWT and tauKQ showed
similar time-dependent increase in fluorescence intensity
(Fig. 5d), suggesting that both can freely redistribute in the
absence of the AIS barrier. Since hyperphosphorylation of
tau can also contribute to somatodendritic mislocalization
of tau [14, 15, 23, 60, 61], we analyzed the phosphorylation
status of tauKQ. Acetyl-mimicking mutations at K274/281
did not alter phosphorylation at S262/S356 (12E8) and














































































































































































Fig. 2 Expression of human K274/281Q tau in transgenic mice destabilizes the AIS cytoskeleton. a, b Levels of expression of human tau in the cortex of
tauWT and tauKQ mice. n = 7-8 mice/group. ***p< 0.001, one-way ANOVA Bonferonni post-hoc analyses. c Representative images of βIV-spectrin and
AnkG immunostaining in the somatosensory cortex of 2 month-old nontransgenic and tauKQhigh mice. Scale bars, 20 μm. d-f Representative images and
quantification of the intensity and length of βIV-spectrin and AnkG immunostaining in the somatosensory cortex of 2 month-old non-transgenic and
tauKQhigh mice. n = 119–132 cells from 6 mice/group. *p< 0.05, **p< 0.01, mixed-model linear regression analyses. Scale bars, 5 μm. g Representative
images of βIV-spectrin and AnkG immunostaining in the somatosensory cortex of 10-12 month-old tauWT and tauKQ mice. Scale bars, 20 μm.
h-j Representative images and quantification of intensity and length of βIV-spectrin and AnkG immunostaining in the somatosensory cortex of 10-12
month-old tauWT and tauKQ mice. n = 109-169 cells from 8 mice/group. *p< 0.05, **p< 0.01, mixed model linear regression analyses. Scale bars, 5 μm.
Values are mean ± SEM
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Phosphorylation at S396/S404 (PHF1) was even signifi-
cantly reduced in tauKQ mice compared to tauWT mice
(Additional file 1: Figure S3A, B). These data support that
acetylation at K274/281 induces somatodendritic mislocali-
zation of tau by mechanisms that are independent of in-
creased tau phosphorylation.
To test whether stabilization of MTs could restore the
AIS barrier function and prevent mislocalization of acety-
lated tau, we treated the neurons expressing tauKQ with a
low dose of epothilone D (EpoD), an MT stabilizer, to re-
duce MT dynamics [36, 37]. Treatment with EpoD pre-
vented the influx of axonal tauKQ into the somatodendritic
compartment (Fig. 5b, c). EpoD also modestly slowed down
the movement of tauKQ to the distal portion of axon
(Fig. 5d). These findings support the importance of MT sta-
















































Fig. 4 K274/281Q tau increases tubulin dynamics in the AIS.
a Representative images of a rat primary neuron co-transfected with
mApple-tauWT or -tauKQ and GFP-tubulin. White boxes indicate the
portion of the AIS (revealed by anti-neurofascin) where GFP-tubulin
was photobleached. b Representative images of photobleaching
and fluorescence recovery of GFP-tubulin in a ~5-μm portion of
the AIS in rat primary neurons transfected with mApple-tauWT or
-tauKQ. c Quantification of FRAP of GFP-tubulin in the AIS of rat
primary neurons co-transfected with mApple-tauWT or -tauKQ and
GFP-tubulin. n = 25–26 cells/group from three independent experiments.
**p< 0.01, mixed model linear regression analysis. Values are mean ±
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Fig. 3 K274/281Q tau increases MT dynamics in primary neurons.
a–d Measuring MT dynamics with GFP-EB3 in rat primary neurons.
a Representative images of HeLa cells co-transfected with mApple-
tauWT or -tauKQ and GFP-EB3. Panels on the right show enlarged
images of GFP-EB3 comets within the white boxes. Scale bars, 5 μm.
b Movement of an individual GFP-EB3 comet (arrowheads) Scale bar,
2 μm. c, d Quantification of GFP-EB3 movement rate and tau levels
in rat primary neurons co-transfected with GFP-EB3 and mApple-tau.
n = 11–13 cells/group from two independent experiments. *p < 0.05,
one-way ANOVA with Tukey’s post hoc test. Values are mean ± SEM
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Discussion
AIS integrity was perturbed in AD brains with increased
tau acetylation. AnkG and βIV-spectrin are essential for
AIS integrity since depletion of either AnkG or βIV-
spectrin dismantles the AIS [62–64]. AnkG and βIV-
spectrin levels were decreased in human AD brains, con-
sistent with a report that the AIS filtering machinery was
impaired in mouse and cellular models of AD [24, 25].
The level of acetylated tau increases as AD pathology
proceeds [28] and, in particular, ac-K274 tau accumulates
in human brains with tau inclusions (Additional file 1:
Figure S1 A-C). In human AD brains, we found that ele-
vated levels of both ac-K274 and ac-K281 tau were corre-
lated negatively with the levels of AnkG and βIV-spectrin.
TauKQ-expressing mice had reduced levels of the cyto-
skeletal proteins AnkG and βIV-spectrin in the AIS com-
pared to non-transgenic and tauWT mice with matching
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Fig. 5 Stabilization of MTs reduces somatodendritic mislocalization of K274/281Q tau. a–d Photoconversion of mEOS2-tau and its movement in rat primary
neurons. a Schematic diagram of photoconversion of mEOS2-tau in the AIS and monitoring its movement toward the somatodendritic compartment and
distal axon. b Time-lapse live images of mEOS2-tauWT, -tauKQ, and -tauKR before and after photoconversion in an axon segment ~30 μm from the AIS.
The last row represents photoconversion of mEOS2-tauKQ after EpoD treatment (20 nM). White circles indicate the somatodendritic compartment. Scale
bars, 10 μm. c, d Quantification of fluorescent intensity in the somatodendritic compartment (c) and distal axon (d) for 30 min after photoconversion of
mEOS2-tau in rat primary neurons. n = 8–21 cells/group from three to nine independent experiments. *p< 0.05, **p< 0.01, mixed model linear regression
analyses. Values are mean ± SEM
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K274/281 tau in AIS perturbation. This functional connec-
tion between acetyl-K274/281 tau and AIS perturbation is
a novel finding that is distinct from roles of other lysine
acetylation such as acetyl-K174, which slows down tau
turnover and promotes its accumulation [54]. Mimicking
acetyl-K274/281 did not change steady-state levels of tau
in neurons (Fig. 3d), supporting the notion that these
distinct effects are likely to depend on the location of the
lysine residue [53]. Since the AIS cytoskeleton is critical for
maintaining axonal-dendritic asymmetry [18], the downreg-
ulation of AIS cytoskeletal proteins in human and mice indi-
cates that sorting of neuronal proteins that require polarized
distribution may be impaired in AD brains with increased
acetylated tau.
Pathogenic mutations increase MT turnover and per-
turb MT stability in transgenic mice expressing human
P301S or P301L tau [36, 37]. However, little is known
about the underlying mechanisms. In primary neurons,
our current study showed that acetyl-mimicking K274/
281Q tau led to elevated MT movements compared with
cells expressing WT tau, suggesting that the acetylation
of K274 and K281 promotes MT hyperdynamicity. Neu-
rons are highly polarized cells and MT dynamics in a
neuron varies depending on the subcellular location
[65]. Unlike those in dendrites and distal axons, MTs in
the AIS are highly stable [59, 66]. Tau acetylated at K274
and K281 reduced the stability of MTs in the AIS, as
measured with site-specific FRAP to monitor tubulin
dynamics. Destabilization of MTs in the AIS has been
demonstrated by increased EB3 mobility in a cellular
model of AD [25]. Our findings advance the understand-
ing of the mechanism underlying AIS dysregulation by
identifying key sites of tau acetylation that induces MT
hyperdynamicity in the AIS. A recent study on single-
molecule tracking of tau has revealed a short dynamic
interaction (~40 ms) of tau with MTs [67]. Acetylation
at K274/281 could change this short interaction between
tau and MTs, resulting in alteration of the association/
dissociation kinetics of other MT-binding molecules that
control MT dynamics such as EB3.
How does acetylated tau destabilize MTs, AnkG, and
βIV-spectrin in the AIS? MTs and the submembranous
cytoskeleton appear to be both physically and functionally
connected. MT bundles in the AIS are densely coated with
an actin-based cytoskeletal network that contains AnkG
and βIV-spectrin [20]. EB1 and EB3 may connect MTs to
AnkG, and EB1/3 knockdown leads to downregulation of
AnkG in the AIS [59]. On the other hand, a mutation in
ankyrin disrupts MT organization in C. elegans [68]. Tau
interacts with EB1 and EB3 and augments their binding to
MTs [69]. One likely mechanism could be that acetyl-
K274/281 tau reduces EB1/3 binding to MTs, leading to
destabilization of MT and downregulation of AnkG and
βIV-spectrin in the AIS. Considering tau’s potential role in
connecting MTs and actin-based cytoskeletal networks
[70] and its interaction with actin filament [31, 71, 72], it
is also possible that, independently of EB1/3, the AIS cyto-
skeleton in the proximity of the membrane might be
destabilized by altered direct binding of acetylated tau to
submembranous cytoskeletal networks consisting of actin,
AnkG, and βIV-spectrin after its detachment from MTs in
the AIS. Tau can interact with proteins in the membrane
of the AIS since tau is shown to be associated with the
membrane when tau is hypo-phosphorylated [73, 74].
Interestingly, K274/281Q tau reduces phosphorylation of
S396/S404 (Additional file 1: Figure S3A, B), raising a
possibility of increased association of acetyl-K274/281 tau
with proteins in the vicinity of the membrane. On the
other hand, since tau is intrinsically disordered and has
multiple binding partners, including enzymes involved in
signaling pathways [35, 75], acetyl-K274/281 tau can exert
an indirect effect on AIS destabilization by disturbing
signal transduction. For instance, tau can bind to histone
deacetylase-6 (HDAC6) and inhibit the enzymatic activity
of HDAC6, which may regulate MT stability via tubulin
acetylation [76].
Does tau acetylation alter other posttranslational modifi-
cations of tau such as phosphorylation? Somatodendritic
mislocalization of tau also depends on the phosphorylation
state of tau [60, 61]. Axonal tau crosses the AIS barrier and
is mislocalized to the somodendritic compartment after
pharmacological treatment that increases tau phosphoryl-
ation [23]. Pseudophosphorylation at KXGS motifs of tau is
sufficient to induce its somatodendritic mislocalization [23].
The effect of acetylation on the phosphorylation status of
tau is lysine-specific: Acetylation at lysines of KXGS motifs
(K259/K353) blocks phosphorylation at the adjacent serines
in the KXGS motifs (S262/S356) [53] whereas acetylation
at K174 does not alter phosphorylation at S262/S356 but
increases phosphorylation at S202/T205 [54]. We observed
that acetylation-mimicking mutations at K274/281 did not
change phosphorylation at S262/S356 in the KXGS motifs
(12E8) as well as S202/T205 (AT8) in the cortex of tauKQ
mice whereas phosphorylation at S396/S404 (PHF1)
was decreased in tauKQ mice compared to tauWT mice
(Additional file 1: Figure S3A, B). These findings dem-
onstrate that acetylation at K274/281 plays a pivotal
role, not secondary to tau phosphorylation, in somato-
dendritic mislocalization.
Our finding that MTs in the AIS are critical for axonal
retention of tau is consistent with the notion that they form
a retrograde barrier that keeps axonal tau from entering the
somatodendritic compartment [23]. Acetylated tau destabi-
lizes this MT-based barrier in the AIS and thus could enter
the somatodendritic compartment. MT stabilization with
EpoD restored this barrier function and prevented misloca-
lization of acetylated tau. Pharmacological MT stabilization
reduces tau binding to MTs, and EpoD dissociates tau from
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MTs [77, 78]. Increased diffusion of MT-free tau could
contribute to circumvention of the MT-based barrier in the
AIS [23]. However, low-dose EpoD prevented acetylated
tau from mislocalization – a finding that emphasizes the
importance of MT stability in the barrier function for reten-
tion of axonal tau. Since the submembrane AIS cytoskel-
eton functions as a filter controlling cytoplasmic transport
in a neuron [22], reduction of AnkG and βIV-spectrin levels
by acetyl-K274/281 tau might also contribute to tau
mislocalization. MT stabilization with EpoD prevented
tau mislocalization and thus might increase the stability
of interconnected AIS submembrane cytoskeletal net-
works. Our findings suggest that acetylated tau has an
active role in disturbing stability of MTs in the AIS,
resulting in circumvention of MT-based barrier in the
AIS and consequent loss of polarized localization.
Conclusions
This study shows that AD-relevant acetylation of tau at
K274 and K281 has a critical role in destabilization of
AIS cytoskeleton concomitant with loss of polarized dis-
tribution of tau. AIS-specific cytoskeletal proteins were
downregulated in the brains of both human AD patients
and transgenic mice expressing an acetyl-tau mimic. The
mutant tau that mimics acetylation (K274/281Q) had
reduced affinity for MTs and increased MT dynamics in
the AIS. Destabilization of the AIS cytoskeleton resulted
in mislocalization of K274/281Q tau into the somato-
dendritic compartment. Pharmacological stabilization of
MTs prevented tau mislocalization. Our findings support
aberrant tau acetylation as a novel mechanism by which
neuronal polarity is compromised in the pathogenesis of
neurodegenerative diseases.
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Additional file 1: Figure S1. Ac-K274 tau inclusions in human tauopathy
brains. (A-C) Representative images of ac-K274 tau immunostaining in the
inferior temporal cortex of human tauopathy brains. Scale bars, 50 μm. (A)
Cytoplasmic tau inclusions (arrows) in the brain of an FTDP-17 patient. (B)
Corticobasal bodies (arrows) in a patient with the A152T tau mutation. (C)
Neurofibrillary tangles (arrows) in an AD brain. Scale bars, 50 μm. Figure S2.
K274/281Q tau has reduced affinity for MTs. (A) Representative images of
co-localization of GFP-tubulin and mApple-tauWT in a HeLa cell. (B–D)
MT-binding assay in HeLa cells co-transfected with GFP-tau mutant and
mApple-tauWT. (B) Representative images of HeLa cells co-transfected with
GFP-tauK274/281Q or -tauK274/281R and mApple-tauWT. GFP-tauK274/
281Q is distributed diffusely in the cytoplasm. mApple-tauWT appears to
bind to MTs. (C,D) Quantification of MT-unbound tau and levels of tau in
HeLa cells co-transfected with GFP-mutant tau and mApple-tauWT. 4KQ(N)
denotes GFP-tauK163/174/180/190Q. n = 60–90 cells/group from two to
three independent experiments. ***p < 0.001, one-way ANOVA with
Dunnett’s post-hoc analyses. Values are mean ± SEM Scale bars, 10 μm.
Figure S3. Levels of phosphorylated tau in tauWT and tauKQ mice. (A,B)
Representative western blots and quantification of levels of phosphorylated
human tau in the cortex of 12-13 month-old tauWT and tauKQ mice. The
antibodies 12E8, AT8, and PHF1 recognize phosphorylated S262/S356, S202/
T205, and S396/S404, respectively, on human tau. n = 8 mice/group.
***p < 0.001, unpaired t test. Values are mean ± SEM (C). (PDF 6517 kb)
Additional file 2: Movie 1. mEOS2-tauWT movement in a rat primary
neuron. Time-lapse images of red mEOS2-tauWT were taken every 30 sec
for 25 min after photoconversion. Location of the cell body is indicated
by the dashed circle. Scale bar, 10 μm. (MP4 25 kb)
Additional file 3: Movie 2. mEOS2-tauK274/281Q movement in a rat
primary neuron. Time-lapse images of red mEOS2-tauKQ were taken
every 30 sec for 25 min after photoconversion. Location of the cell body
is indicated by the dashed circle. Scale bar, 10 μm. (MP4 44 kb)
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